Vaxxinity, Inc., a biopharmaceutical firm listed on NASDAQ under the ticker VAXX, has reported encouraging clinical trial outcomes for its UB-312 drug candidate
Novo Nordisk has announced encouraging results from its Phase I clinical trial for a novel obesity treatment, amycretin, at its Capital Markets Day event.
FSD Pharma has submitted a Clinical Trial Application (CTA) for a Phase-1b study, the METAL-1 TRIAL, to evaluate the safety and efficacy of its dietary supplement, unbuzzd™.